This is a routine scientific update with no new regulatory or commercial catalysts. Monitor for upcoming full results from ACACIA-HCM (nHCM) and potential FDA discussions, which could be more material. No immediate trading action warranted.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 11 $74.56entry
- T+1 · 6mo ago +0.34%α +0.47% · $74.81
- T+5 · 6mo ago +0.83%α +0.92% · $75.18
- T+20 · 5mo ago −8.19%α −7.89% · $68.45
- T+60 · 3mo ago +5.75%α +1.36% · $78.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cytokinetics presented new data at ESC Heart Failure 2026 reinforcing the clinical profile of MYQORZO (aficamten) in obstructive HCM, including superiority over metoprolol in MAPLE-HCM, long-term safety in FOREST-HCM, and favorable left atrial remodeling in SEQUOIA-HCM. The press release is a routine scientific update with no new regulatory or financial catalysts, and the stock impact is likely muted given the absence of material commercial or regulatory news.
Key Facts
- MAPLE-HCM showed aficamten significantly improved exercise capacity, outflow gradients, and NT-proBNP across all doses, while metoprolol showed no improvement.
- FOREST-HCM open-label extension data (up to 96 weeks) showed no increase in arrhythmias, including NSVT or atrial fibrillation, with aficamten.
- SEQUOIA-HCM analysis showed aficamten significantly improved left atrial reservoir strain (+2.9%; p=0.004) and conduit strain (+2.2%; p=0.001) vs placebo.
- Real-world evidence from 273 patients showed 26.6% activity impairment due to oHCM, with higher impairment in obstructive vs non-obstructive HCM (30.2% vs 19.2%; p=0.0003).
- MYQORZO is already approved in the U.S., EU, and China for symptomatic oHCM; no new regulatory actions were announced.
Financial Impact
No financial figures disclosed; data reinforces existing clinical profile without changing revenue or guidance.
Risk Factors
- Competition from other cardiac myosin inhibitors (e.g., mavacamten) could limit market share.
- Potential safety concerns from boxed warning on heart failure risk may constrain adoption.
- Regulatory setbacks in expanding indications (nHCM, pediatric) could disappoint expectations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292055 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers